Liver health plays an important role in maintaining the body's normal functions, including digestion, metabolism, and the removal of harmful substances. However, infections such as hepatitis C can gradually affect liver function and lead to long-term complications when left untreated. With advancements in antiviral medicine, patients now have access to treatment options that target the virus more directly and help improve clinical outcomes.
A myhep all is a prescription antiviral medicine containing two active ingredients, Sofosbuvir and Velpatasvir. Manufactured by Mylan, this combination is used to treat chronic hepatitis C virus (HCV) infection in eligible patients. It is a generic formulation associated with the same active ingredient combination found in Epclusa. Medixo Centre provides product information and pharmaceutical supply assistance for this and other specialty medicines through its wholesale and export services.
Composition and Key Product Details
MyHep All combines two antiviral agents in a single tablet. Each tablet contains:
-
Sofosbuvir 400 mg: An antiviral ingredient that inhibits the NS5B RNA-dependent RNA polymerase enzyme. This enzyme plays an important role in hepatitis C viral replication.
-
Velpatasvir 100 mg: An NS5A inhibitor that interferes with viral replication and other processes required for the hepatitis C virus to multiply.
The combination targets two different viral proteins, making it an important treatment option for different hepatitis C genotypes.
According to the product information provided by Medixo Centre, the medicine is manufactured by Mylan, requires a prescription, and is supplied in a pack containing 28 tablets.
Therapeutic Applications of MyHep All
Hepatitis C is a viral infection that primarily affects the liver. Some individuals may experience symptoms, while others can remain unaware of the infection for years. Without suitable treatment, chronic infection may increase the risk of liver fibrosis, cirrhosis, and other complications.
The Sofosbuvir and Velpatasvir combination is a pangenotypic antiviral treatment, meaning it is designed to work against all six major hepatitis C virus genotypes.
Doctors may prescribe this combination for eligible adults with different stages of liver disease. Treatment selection depends on factors such as previous antiviral therapy, the presence of cirrhosis, liver function, and other medical conditions.
In certain clinical situations, healthcare professionals may prescribe ribavirin alongside the combination. This decision depends on the patient's condition and established treatment recommendations.
How the Two Antiviral Ingredients Work
The effectiveness of combination antiviral therapy comes from targeting different stages of viral activity.
Sofosbuvir blocks the NS5B polymerase enzyme, which the hepatitis C virus needs to reproduce its genetic material. By interfering with this process, the medicine helps reduce viral multiplication.
Velpatasvir works differently by targeting the NS5A protein. This protein is involved in viral replication and the formation of new viral particles. Blocking its activity provides an additional mechanism for controlling the infection.
Together, these ingredients help suppress the hepatitis C virus and support the possibility of achieving a sustained virological response. This refers to an undetectable viral load after the prescribed treatment and follow-up period.
Dosage and Administration Guidelines
The commonly recommended adult regimen for eligible patients is one tablet containing Sofosbuvir 400 mg and Velpatasvir 100 mg once daily. Treatment is often prescribed for 12 weeks, although individual circumstances can affect the recommended regimen.
Patients should follow their doctor's instructions and keep the following points in mind:
-
Take the tablet at approximately the same time every day.
-
It can generally be taken with or without food.
-
Swallow the tablet whole with water.
-
Avoid changing the prescribed dose independently.
-
Inform the doctor about all prescription medicines, supplements, and herbal products.
-
Complete the treatment according to the prescribed schedule.
Patients who miss a dose should follow their healthcare professional's advice rather than taking extra tablets without guidance.
Safety Precautions and Possible Side Effects
Before beginning treatment, patients should discuss their medical history with their healthcare provider. Particular attention is necessary for individuals with kidney problems, other liver conditions, HIV infection, or a previous hepatitis B infection.
Hepatitis B reactivation has been reported during treatment with direct-acting antiviral medicines. Appropriate screening is therefore important before therapy begins.
Some commonly reported side effects include headache, fatigue, nausea, and difficulty sleeping. Not every patient experiences these reactions, and their severity may differ.
Drug interactions are another important consideration. For example, amiodarone may cause a serious reduction in heart rate when used with Sofosbuvir-containing treatment. Certain anticonvulsants and acid-reducing medicines may also interfere with treatment effectiveness.
Patients should seek medical advice if they experience unexpected symptoms or suspected adverse reactions.
Medixo Centre: Specialty Pharmaceutical Distribution and Export Services
Medixo Centre is a pharmaceutical wholesaler, exporter, and shipper based in New Delhi, India. The company focuses on specialty pharmaceutical products, including medicines for hepatitis, anti-HIV treatment, cancer care, and transplantation-related healthcare requirements.
Its services are intended for hospitals, clinics, doctors, pharmacies, medical institutions, wholesalers, and pharmaceutical resellers. The company provides product information, ordering assistance, and international medicine delivery support.
Customers can also access services such as order tracking, customer assistance, and information about prescription requirements. According to its website, Medixo Centre offers tracked shipping and sources medicines through authorised dealers and suppliers.
For pharmaceutical buyers, access to product composition, manufacturer details, packaging information, and batch and expiry details can help support informed purchasing decisions. Prescription medicines should always be obtained through appropriate and legally compliant channels.
Supporting Informed Hepatitis C Treatment Decisions
Successful hepatitis C management involves proper diagnosis, selecting an appropriate antiviral regimen, monitoring treatment progress, and completing follow-up testing. Patients should not rely on online product descriptions to determine their own dosage or treatment suitability.
For healthcare providers and pharmaceutical buyers exploring myhep all , Medixo Centre offers product information and specialty medicine distribution assistance. However, the decision to use this antiviral combination should always be made by a qualified healthcare professional after reviewing the patient's medical history, test results, and possible drug interactions.



